Prognostic Implications of Decreased Microrna-101-3p Expression in Patients with Non-Small Cell Lung Cancer
Hai-Min Lu,Wan-Wan Yi,Yu-Shui Ma,Wei Wu,Fei Yu,Heng-Wei Fan,Zhong-Wei Lv,Hui-Qiong Yang,Zheng-Yan Chang,Chao Zhang,Wen-Ting Xie,Jun-Jian Jiang,Ying-Chun Song,Li Chai,Cheng-You Jia,Gai-Xia Lu,Xiao-Jun Zhong,Li-Kun Hou,Chun-Yan Wu,Min-Xin Shi,Ji-Bin Liu,Da Fu
DOI: https://doi.org/10.3892/ol.2018.9559
2018-01-01
Oncology Letters
Abstract:To investigate the expression level of microRNA-101-3p (miR-101-3p) and its possible association with progression, prognosis and chemotherapy in patients with non-small cell lung cancer (NSCLC), the Gene Expression Omnibus (GEO) database was used. Quantitative polymerase chain reaction was used to verify the expression in 327 NSCLC and 42 adjacent normal lung tissues, of which 42 viable tissues were paired with nearby normal lung tissues. Based on the Cox regression model, univariate and multivariate analyses were used to address the factors that had effects on overall survival (OS) and disease-free survival (DFS) rate. Data from the GEO database demonstrated that the miR-101-3p expression in NSCLC was downregulated, compared with normal lung cancer. Survival analysis through univariate and multivariate models indicated that the miR-101-3p expression level was a crucial risk factor for OS and DFS in patients with NSCLC. A number of clinical parameters were determined to be associated with miR-101-3p expression, including tumor diameter, lymph node metastasis and tumor-node-metastasis stage. Adjuvant chemotherapy with high expression of miR-101-3p was determined to increase OS and DFS in patients with NSCLC, compared with patients with de novo or low expression of miR-101-3p. The present results demonstrated that miR-101-3p expression levels were associated with NSCLC progression and prognosis, which indicated that miR-101-3p may serve as a biomarker for patients with NSCLC who have received adjuvant chemotherapy.